Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects Of ATH-1105 In Models Of ALS At Motor Neurone Disease Association's International Symposium On ALS/MND
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects Of ATH-1105 In Models Of ALS At Motor Neurone Disease Association's International Symposium On ALS/MND
Athira Pharma在運動神經元疾病協會的國際ALS/MND研討會上展示了ATH-1105在ALS模型中突出的神經保護效果的臨床前數據。
Athira Pharma, Inc. (NASDAQ:ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highlighting target engagement and neuroprotective effects of ATH-1105 in human motor neurons at the Motor Neurone Disease Association's 35th International Symposium on ALS/MND, taking place Dec. 6-8, 2024, in Montreal, Canada.
Athira Pharma, Inc.（納斯達克：ATHA），一家專注於開發小分子藥物以恢復神經健康和減緩神經退行性的臨床階段生物製藥公司，今天在加拿大蒙特利爾舉行的ALS/MND國際研討會上，展示了ATH-1105在人類運動神經元中的靶點誘導和神經保護效應的臨床前數據。該研討會將於2024年12月6日至8日舉行。
資訊熱榜
更新時間